Loading...

PTC Therapeutics Announces Initiation of a Registration-Directed Clinical Trial to Evaluate Vatiquinone in Mitochondrial Epilepsy

Print Friendly, PDF & Email

RE: MITOCHONDRIAL EPILEPSY- Global Phase 2/3 trial now enrolling patients with highly morbid unmet medical condition – PR Newswire SOUTH PLAINFIELD, N.J., Oct. 26, 2020 SOUTH PLAINFIELD, N.J., Oct. 26, 2020 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced the initiation of a registration-directed Phase 2/3 clinical trial to evaluate […]